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Abstract
Malignant astrocytomas are the most aggressive primary brain tumors with a poor prognosis despite optimal
treatment. Dysfunction of mismatch repair (MMR) system accelerates the accumulation of mutations throughout the
genome causing uncontrolled cell growth. The aim of this study was to characterize the MMR system defects that
could be involved in malignant astrocytoma pathogenesis. We analyzed protein expression and promoter methylation
of MLH1, MSH2 and MSH6 as well as microsatellite instability (MSI) and MMR gene mutations in a set of 96 low- and
high-grade astrocytomas. Forty-one astrocytomas failed to express at least one MMR protein. Loss of MSH2
expression was more frequent in low-grade astrocytomas. Loss of MLH1 expression was associated with MLH1
promoter hypermethylation and MLH1 -93G>A promoter polymorphism. However, MSI was not related with MMR
protein expression and only 5% of tumors were MSI-High. Furthermore, the incidence of tumors carrying germline
mutations in MMR genes was low and only one glioblastoma was associated with Lynch syndrome. Interestingly,
survival analysis identified that tumors lacking MSH6 expression presented longer overall survival in high-grade
astrocytoma patients treated only with radiotherapy while MSH6 expression did not modify the prognosis of those
patients treated with both radiotherapy and chemotherapy. Our findings suggest that MMR system alterations are a
frequent event in malignant astrocytomas and might help to define a subgroup of patients with different outcome.
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Introduction
Malignant gliomas account for 70% of all primary brain
tumors with an incidence rate adjusted to the European
Standard Population of 5.27 per 100 000 persons per year [1].
Unfortunately, the majority of these patients display
progressive disease and subsequent death. The most common
and devastating brain tumor in adults is glioblastoma (grade IV)
with a median survival of approximately 12-14 months despite
optimal treatment [2,3]. Patients with anaplastic astrocytoma
(grade III) survive for nearly 1.5 years, and those with low-
grade astrocytomas (grade II) can survive for as long as 5-10
years [4,5]. Initiation and progression of malignant
astrocytomas are related to their genetic and chromosomal
alterations. In this context, recent molecular and genetic
studies have identified different markers that help to determine
prognosis and likelihood of therapeutic response [6-10].
Mismatch repair (MMR) system maintains DNA stability by
repairing DNA mismatches and insertion/deletion loops
acquired during DNA replication. Therefore, MMR system
maintains genomic integrity and provides tumor suppressor
functions. Defective MMR function is found both in sporadic
tumors and in cancers related to Lynch syndrome [11] that is
characterized by a predisposition to early onset tumors in the
proximal colon as well as extracolonic malignancies such as
astrocytomas [12-14]. This syndrome is due to germline
mutations in one of the MMR genes, mostly MSH2 or MLH1,
and less frequently MSH6 or PMS2 [15,16]. Mutations in these
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genes result in microsatellite instability (MSI) and/or loss of
expression of the associated protein. However, MMR
deficiency in sporadic cancers is mostly due to loss of MLH1
expression as a result of somatic hypermethylation of its
promoter [16]. MLH1 promoter hypermethylation has been
associated in colorectal cancer (CRC) with the MLH1 -93G>A
promoter polymorphism [17,18].
We have performed a molecular characterization of MMR
system defects in malignant astrocytomas and we have
evaluated the influence of these alterations in patient outcome.
Specifically, we have investigated the expression profile and
the promoter hypermethylation status of MLH1, MSH2 and
MSH6 genes, as well as the MSI levels in pretreated low- and
high-grade primary astrocytomas. We have also conducted a
mutational analysis of MMR genes in tumors with MMR
defective function.
Materials and Methods
Ethics Statement
The study was approved by the local Ethics Committees of
the University Hospital of Salamanca (Salamanca, Spain) and
University Hospital 12 de Octubre (Madrid, Spain), and written
consent was obtained from the patients. The study was
conducted according to the principles expressed in the
Declaration of Helsinki.
Patients and samples
A total of 96 newly diagnosed patients with primary
astrocytoma grades II to IV (study cohort) were recruited from
June 2000 until March 2006 at the University Hospital of
Salamanca (Spain). Patients were followed up from diagnosis
to the present at the Neurosurgery and Oncology Departments.
Tumors were classified as 20 low-grade astrocytomas (grade
II), 19 anaplastic astrocytomas (grade III) and 57 glioblastomas
(grade IV) according to the 2007 WHO classification [19]. The
clinicopathological features of the patients are summarized in
Table 1 and Table S1.
An independent cohort of 71 newly diagnosed patients with
primary astrocytomas WHO grades III and IV (12 anaplastic
astrocytomas and 59 glioblastomas) [19] was explored to
validate the prognostic results. Patients were admitted from
April 2004 until December 2010 to the University Hospital 12
de Octubre (Madrid, Spain) and followed up from diagnosis to
the present at the Neurosurgery and Oncology Departments.
The clinical characteristics of this validation cohort are listed in
Table S1.
All blood and tissue samples were obtained at diagnosis
before initiation of treatment. Matched DNA from peripheral
blood and frozen tumor specimens were extracted by standard
phenol/chloroform procedure. Tumor tissues were also fixed in
formalin and embedded in paraffin for immunohistochemical
analysis.
Tissue microarray design and Immunohistochemistry
Formalin-fixed paraffin-embedded tissue samples of all
patients of the study cohort were used to prepare a tissue
microarray (TMA) made with a tissue arrayer device (Beecher
Instrument, MD). All astrocytomas were histologically reviewed
and three 1-mm-diameter cylinders from different areas of
morphologically representative non-necrotic sites of each tumor
were included to ensure the quality, reproducibility and
homogenous staining of the slides. Thus, 3 different TMA
blocks were constructed, each containing the 96 astrocytomas
and 8 different tissue controls (lymph node, skeletal muscle,
cerebral cortex, cerebellum, spleen, adrenal gland, lung and
kidney). Immunohistochemical staining was performed on
these sections using MLH1 clone G168-15 (BD Pharmingen,
San Diego, CA, USA), MSH2 clone FE11 (Biocare Medical,
Concord, CA, USA) and MSH6 clone BC/44 (Biocare Medical,
Concord, CA, USA) antibodies. MSH6 immunohistochemical
staining was also performed in formalin-fixed, paraffin-
embedded tumor tissue sections from the 72 patients in the
validation cohort. MMR protein expression was evaluated
semiquantitatively by a pathologist (A.S-B) and an author (I.R-
H) blinded to clinical and molecular information and
disagreements between reviewers were resolved by the
analysis of the slides by a third author (R.G-S). Tumor area
was considered positive when there was obvious nuclear
staining in more than 50% of tumor cells. Staining of nuclei of
adjacent normal cells and tumor-infiltrating lymphocytes was
used as internal positive controls. Figure 1 shows
representative examples of low- and high-grade astrocytomas
staining.
Table 1. Summary of astrocytoma patient characteristics.
Patients, No. (%) LGA (n=20) AA (n=19) GBM (n=57)
Sex    
Male 11 (55) 12 (63) 36 (63)
Female 9 (45) 7 (37) 21 (37)
Median age, years [quartiles] 35 [30.3-46.0] 57 [47.0-66.0] 63 [54.5-69.0]
Tumor Region    
Temporal 7 (35) 7 (37) 20 (35)
Frontal 6 (30) 5 (26) 22 (39)
Parietal 2 (10) 1 (5) 6 (10)
Occipital 0 (0) 2 (11) 5 (9)
Other 5 (25) 4 (21) 4 (7)
Tumor Side    
Right 8 (40) 10 (53) 34 (60)
Left 7 (35) 5 (26) 19 (33)
Other 5 (25) 4 (21) 4 (7)
Surgery    
Total resection 12 (60) 13 (69) 41 (72)
Subtotal resection 7 (35) 5 (26) 12 (21)
Partial resection 1 (5) 1 (5) 4 (7)
Treatment    
No treatment 10 (50) 4 (21) 5 (9)
Radiotherapy 5 (25) 8 (42) 39 (68)
Radiotherapy and Chemotherapy 5 (25) 7 (37) 13 (23)
LGA: low-grade astrocytoma, AA: anaplastic astrocytoma, GBM: glioblastoma.
doi: 10.1371/journal.pone.0076401.t001
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Methylation-specific multiplex ligation-dependent
probe amplification (MS-MLPA)
The SALSA MS-MLPA Kit ME011 (MRC-Holland) was used
to detect aberrant methylation in MLH1, MSH2 and MSH6
promoter regions using probes that recognized sequences
containing a methylation-sensitive HhaI restriction site. The kit
included 5 specific probes for MLH1 (located at -659, -383,
-246, -13 and +206 relative to initiating ATG), 3 probes for
MSH2 (located at -269, -193 and +124 to initiating ATG) and 3
probes for MSH6 promoter region (located at -317, -126 and
-32 to initiating ATG). All reactions were carried out as
described by the manufacturer with minor modifications using
in each reaction 150 ng of tumor DNA. PCR reaction fragments
were separated by capillary gel electrophoresis (ABI Prism
3100 Genetic Analyzer, Applied Biosystems) and quantified
using Genemapper software (Applied Biosystems). MS-MLPA
processing was performed using Coffalyser analysis tool
developed at MRC-Holland and tumor samples with a cut off
value >0.75 was considered to be extensively hypermethylated
as described by Jeuken et al [20]. For MLH1 analysis,
methylation status was calculated considering only the two
specific probes related to gene silencing (-246 and -13
positions corresponding to C and D promoter regions) [21].
Determination of MLH1 -93G>A genotype
Genotyping was performed using DNA extracted from
peripheral blood of 96 patients and 200 sex-matched healthy
subjects over 60 years old without history of cancer. MLH1
-93G>A promoter polymorphism (rs1800734) status was
determined using TaqMan SNP Genotyping Assay ID
C_7535141 (Applied Biosystems) containing sequence-specific
forward and reverse primers to amplify the polymorphic
sequence and two probes labeled with VIC and FAM dyes to
detect both alleles [22]. PCR reactions were carried out using
TaqMan universal PCR Master Mix (Applied Biosystems)
following manufacturer’s instructions in a Step-One Plus Real-
time PCR system (Applied Biosystems). Genotype distribution
in the control group was within the Hardy-Weinberg equilibrium
(P > 0.1).
Microsatellite Instability (MSI)
MSI was assessed by PCR in paired peripheral blood and
tumor DNA obtained from 88 patients using a panel of 8
markers: 3 mononucleotide markers (BAT25, BAT26 and
BAT40), 3 dinucleotide markers (D2S123, D5S346 and
D17S250) and 2 tetranucleotide markers (MYCL and PAX6).
This MSI marker set included the National Cancer Institute
recommended markers for MSI detection in Lynch syndrome
[11,23]. The 5’ antisense primers were labeled with FAM for
BAT26, D5S346, D17S250 and D2S123, HEX for BAT40,
MYCL and PAX6, and TET for BAT25. PCR reactions were
performed using the Go Taq Hot Start Polymerase (Promega).
PCR products were separated using an ABI Prism 3100
Genetic Analyzer (Applied Biosystems) and results were
analyzed with Genemapper software (Applied Biosystems).
Tumors were classified as MSI-High (MSI-H) if ≥ 30% markers
demonstrated instability, MSI-Low (MSI-L) if < 30%
demonstrated MSI, and microsatellite stable (MSS) if no
Figure 1.  Representative images of hematoxylin and eosin (H&E), MLH1, MSH2 and MSH6 staining on paraffin-embedded
sections of samples from representatives low-grade astrocytomas (grade II) (A-D) and glioblastomas (grade IV) (E-H)
according to the 2007 WHO classification [19].  Low-grade astrocytomas are well differentiated and slow-growing tumors with
absence of necrosis and microvascular proliferation, whereas high-grade astrocytomas are characterized by high cellularity and
mitotic activity, necrosis and microvascular proliferation (arrows). MLH1, MSH2 and MSH6 expression was visualized by staining
with specific antibodies and their expression was considered positive when nuclear staining was detected in more than 50% of
tumor cells (Magnification x400).
doi: 10.1371/journal.pone.0076401.g001
Mismatch Repair System and Astrocytomas
PLOS ONE | www.plosone.org 3 September 2013 | Volume 8 | Issue 9 | e76401
marker exhibited MSI according to the established criteria for
MSI determination [11,23].
Mutational analysis of MLH1, MSH2 and MSH6 genes
Mutational analysis of MMR genes was performed by PCR-
CSGE (Conformation-Sensitive Gel Electrophoresis) [24] in
tumor DNA of patients with negative immunohistochemical
staining for MLH1, MSH2 and/or MSH6 and in patients with
MSI-H tumors. Those samples that showed a mobility shift in
the CSGE analysis were additionally analyzed by direct
sequencing to identify the nature of mutations. In addition, DNA
extracted from peripheral blood was analyzed to determine the
somatic or germline origin of tumor mutations. Primers
sequences are available upon request.
Statistical analysis
In most analysis, WHO grade III and IV astrocytomas are
analyzed together as high-grade astrocytomas. The results
were expressed as percentages for categorical variables and
as medians [quartiles] for continuous variables. Associations
between molecular and clinicopathological features as well as
Hardy-Weinberg equilibrium were analyzed using the χ2
contingency test and the Fisher’s exact test when necessary
(expected values below 5). Survival models were used to find
clinical and/or molecular parameters related to overall survival
(OS). OS was defined as the time between diagnosis and
death or last follow-up. Those patients lost during follow-up
were censored at the last known follow-up date and patients
with a survival time lesser than 30 days were eliminated since
these patients might have died for reasons other than the
disease itself. Survival curves were estimated by the Kaplan
Meier method and compared among patient subsets using the
log-rank test. Multivariate Cox model was used to identify
independent prognostic factors correlated with survival in
astrocytoma patients. All categories were first ordered from
good to bad with respect to prognosis. Then the corresponding
Hazard Ratios (HR) will be greater than one helping the
interpretation. Differences with a P-value <0.05 were
considered as statistically significant and all tests were two-
sided. All statistical analyses were performed using SPSS
software.
Results
MMR protein expression
MLH1, MSH2 and MSH6 protein expression was determined
in the 96 tumor tissues included in the tissue microarray.
Analysis of MMR protein expression showed that 41 tumors
(43%) presented loss of expression of at least one MMR
protein. Loss of MLH1 expression was observed in 17 cases
(18%), MSH2 in 21 cases (22%) and MSH6 in 31 cases (32%).
In addition, 10 tumors failed to express two MMR proteins
simultaneously (MLH1 and MSH2 expression were lost in 1
case, MLH1 and MSH6 expression in 4 cases, and MSH2 and
MSH6 expression in 5 cases). Nine tumors did not express the
three MMR proteins. Furthermore, MSH2 negative staining was
significantly more frequent in low-grade astrocytomas (45%)
than in high-grade astrocytomas (16%) (P=0.012), whereas
MLH1 and MSH6 expression were not associated with tumor
histopathology (Table 2).
MMR promoter methylation
MMR promoter methylation was studied in 92 patients.
Promoter hypermethylation of MLH1 was present in 11 cases
(12%), MSH2 in 11 cases (12%) and MSH6 in 8 cases (9%).
No differences in MMR methylation levels were identified
between different tumor grades. Methylation status of MLH1
promoter was significantly associated with loss of MLH1
expression (P=0.021). Specifically, 46% of tumors with MLH1
promoter hypermethylation showed lack of MLH1 expression
(Table 2). We did not find any association between MSH2 and
MSH6 promoter methylation and their protein expression
(Table 2).
Analysis of MLH1 -93G>A polymorphism
MLH1 -93G>A polymorphism was determined in 96
astrocytoma patients and 200 control subjects. The distribution
of genotypes in control samples did not significantly differ from
that expected from Hardy-Weinberg equilibrium. MLH1 -93GG
genotype was found in 57 (60%), GA genotype in 31 (32%) and
AA genotype in 8 (8%) patients. We did not find significant
differences in distribution of MLH1 -93G>A genotypes between
low-grade astrocytomas, anaplastic astrocytomas and control
subjects. However, carriers of the MLH1 -93AA genotype were
more represented in the group of glioblastoma patients
Table 2. Relation between tumor grade, promoter methylation status and MLH1, MSH2 and MSH6 protein expression.
Patients, No. (%) MLH1 Expression MSH2 Expression MSH6 Expression
 Positive Negative P-value Positive Negative P-value Positive Negative P-value
Tumor grade   0.721   0.012   0.805
Low-grade astrocytomas 17 (85) 3 (15)  11 (55) 9 (45)  14 (70) 6 (30)  
High-grade astrocytomas 62 (82) 14 (18)  64 (84) 12 (16)  51 (67) 25 (33)  
Promoter Methylation*   0.021   0.699   0.713
Hypermethylated 6 (54) 5 (46)  8 (73) 3 (27)  5 (62) 3 (38)  
No hypermethylated 70 (86) 11 (14)  64 (79) 17 (21)  57 (68) 27 (32)  
(* MLH1, MSH2 and MSH6 expression was associated with MLH1, MSH2 and MSH6 promoter methylation status respectively)
doi: 10.1371/journal.pone.0076401.t002
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(P=0.017) (Table 3). Furthermore, the AA genotype was more
frequent in tumors with MLH1 promoter hypermethylation
(P<0.001) and in tumors that showed lack of MLH1 expression
(P=0.030) (Table 3).
Microsatellite Instability
MSI analysis was performed in 88 cases and revealed that
the most frequent unstable markers in our series were BAT25
(15% of cases) and BAT40 (13% of cases). On the contrary,
BAT26 was unstable in 1% of cases.
Forty-seven patients (53%) were classified as MSS, 37
patients (42%) as MSI-L and 4 patients (5%) as MSI-H, with no
differences between tumor grades. The four MSI-H tumors
were glioblastomas. Three of these cases showed expression
of all MMR proteins and one case presented loss of MSH6
expression. Neither MMR protein expression nor MMR
promoter methylation nor MLH1 -93AA genotype were
associated with MSI status (Table S2).
Germline and somatic mutations of MMR genes
Mutation analysis of MMR genes was performed in the forty-
four tumors that showed abnormalities in MMR protein
Table 3. Distribution of MLH1 -93G>A genotypes according
to diagnostic group, MLH1 promoter hypermethylation and
MLH1 protein expression.
Patients, No. (%) Genotype
 GG + GA AA P-value
Diagnostic group    
LGA 19 (95) 1 (5) 0.540
AA 19 (100) 0 (0) 1.000
GBM 50 (88) 7 (12) 0.017
Controls 193 (96) 7 (4)  
MLH1 Hypermethylation   < 0.001
Hypermethylated 6 (55) 5 (45)  
No hypermethylated 78 (96) 3 (4)  
MLH1 Expression   0.030
Positive 75 (95) 4 (5)  
Negative 13 (76) 4 (24)  
doi: 10.1371/journal.pone.0076401.t003
expression or MSI-H. Six of these tumors carried mutation in
MLH1, MSH2 or MSH6 genes (Table 4). Four tumors
presented MSS with MMR germline mutations and lack of
expression of the associated protein; one glioblastoma with
MSI-L showed two mutations in the MSH2 gene, one mutation
in the MLH1 gene and loss of MLH1, MSH2 and MSH6 protein
expression. The remained case was a MSI-H glioblastoma with
loss of MSH6 expression and a family history of colorectal
cancer. This patient showed a pathogenic germline frameshift
mutation in MSH2 gene and wild-type allele loss in tumor
tissue.
We described for the first time in this study three novel
mutations in MSH2 gene c.1159CG (p.Leu387Val), c.1983delA
(p.Lys661AsnfsX24) and c.1064GA (p.Arg355Lys), and two
novel mutations in MSH6 gene c.4004AC (p.Glu1335Ala) and
c. *(24_28) delGTTGA (Table 4).
Impact of MMR alterations on patient survival
Next, we investigated the prognostic impact of both MMR
alterations and clinical parameters on 92 astrocytoma patients
(20 low-grade astrocytomas and 72 high-grade astrocytomas).
Univariate survival analysis revealed that loss of MSH6
expression was significantly associated with a better median
OS in high-grade astrocytomas (13.8 months vs. 10.1 months)
(Table 5A). Age of patients (<60 years vs. ≥60 years) and
treatment (radiotherapy and chemotherapy vs. radiotherapy
alone vs. no treatment) were also significantly associated with
OS in high-grade astrocytomas (Table 5A). Furthermore,
multivariate Cox model indicated that MSH6 expression, age
and treatment were statistically significant independent
prognostic factors for OS of high grade-astrocytomas in our
series (Table 5A).
In order to validate the prognostic value of MSH6 expression
on high-grade astrocytomas survival, we evaluated MSH6
protein expression in an independent cohort of 71 high-grade
astrocytomas. Fifteen (21%) of these tumors showed loss of
MSH6 expression (Figure S1). However, survival analysis
revealed that MSH6 expression was not associated with
prognosis, whereas treatment was an independent prognostic
factor for OS and there was marginally significant correlation
between age and OS time in this validation group of patients
(Table 5B).
Table 4. MMR gene mutations identified in tumors with loss of at least one MMR protein expression and/or MSI-H.
MSI Case Gene MMR Germline Mutation MMR Somatic Mutation Pathogenicity Loss of MMR expression
MSS GBM MLH1 c.2146GA (p.Val716Met)[25]  Uncertain MLH1, MSH2
MSS LGA MSH2 c.1159CG (p.Leu387Val)  Uncertain MSH2
MSS LGA MSH6 c.4004AC (p.Glu1335Ala)  Uncertain MLH1, MSH2, MSH6
MSS GBM MSH6 c. *(24_28)delGTTGA  Uncertain MSH6
MSI-L GBM MLH1  c.1937AG (p.Tyr646Cys)[26] Uncertain MLH1, MSH2, MSH6
  MSH2  c.1983delA (p.Lys661AsnfsX24) Pathogenic  
  MSH2  c.1064GA (p.Arg355Lys) Uncertain  
MSI-H GBM MSH2 c.2239_2240delAT (p.Ile747ArgfsX2)[27] Wt allele loss in tumor Pathogenic MSH6
doi: 10.1371/journal.pone.0076401.t004
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We further analyzed the differences between the study
cohort and the validation cohort of patients in order to unravel
the role of MSH6 protein expression in patients diagnosed of
astrocytoma. We found that the number of patients who
received radiotherapy and chemotherapy was significantly
higher in the validation cohort compared to the study cohort
(Table 6). Consequently, those patients belonged to the
validation cohort had a better outcome compared to the study
cohort (Table 6). Since treatment itself constitute a strong
prognostic marker (Figure 2A), we stratified the entire patient
set by treatment and we analyzed the association between
MSH6 expression and clinical outcome in each treatment
subgroup separately. Loss of MSH6 expression was
associated with a better median OS time in the group of high-
grade astrocytoma patients only treated with radiotherapy
(HR=2.17, 95% C.I. 1.14-4.11, P=0.015) (Figure 2B);
meanwhile no significant differences were found in the group of
patients treated with radiotherapy plus chemotherapy
(HR=1.21, 95% C.I. 0.64-2.26, P=0.558) (Figure 2C). Survival
analysis could not be estimated in the group of patients that did
not receive any treatment due to small number of events.
Discussion
Malignant astrocytomas are one of the most devastating
cancers with a dismal prognosis. Virtually all high-grade
astrocytomas progress and locally relapse regardless of
improved diagnosis and multi-modality treatment approach
[2,3]. Therefore, identification of new markers may contribute to
a better prediction of prognosis and response to therapy.
Astrocytomas are characterized by an infiltrating and
aggressive behavior directly related to their genetic alterations
in core signaling pathways [28]. In this regard, MMR activity
could be implicated in astrocytoma pathogenesis due to the
fact that loss of MMR function accelerates the accumulation of
mutations that are no longer repaired.
We have identified a large number of astrocytomas with
defective MMR system expression. Forty-three percent of
tumors included in our series failed to express at least one
Table 5. Univariate and multivariate survival analysis in
high-grade astrocytomas.
Parameter Univariate Analysis Multivariate Analysis
 HR (95% C.I.) P-value HR (95% C.I.) P-value
A) STUDY COHORT
(n=72)     
MSH6 expression 1.76 (1.01-3.07) 0.045 1.84 (1.05-3.23) 0.033
Age 2.03 (1.18-3.50) 0.009 1.75 (1.02-3.02) 0.042
Treatment 2.53 (1.56-4.11) 0.001 2.42 (1.52-3.87) < 0.001
B) VALIDATION
COHORT (n=71)     
MSH6 expression 1.30 (0.66-2.56) 0.443 1.56 (0.77-3.19) 0.219
Age 1.76 (0.99-3.12) 0.051 1.74 (0.98-3.11) 0.060
Treatment 1.55 (1.01-2.47) < 0.001 1.70 (1.02-2.84) 0.041
doi: 10.1371/journal.pone.0076401.t005
MMR protein at diagnosis, suggesting that this abnormality
could be an intrinsic property of a subgroup of tumors. We also
showed that MLH1 and MSH6 expression profiles were similar
in both low- and high-grade astrocytomas whereas the lack of
MSH2 expression was significantly more frequent in low-grade
astrocytomas. In this sense, it has been previously reported an
increased expression of MSH2 in high-grade astrocytomas
compared with low-grade astrocytomas. Therefore, up-
regulation of MSH2 levels may be related to an increased cell
proliferation rate in astrocytomas [29,30]. Although MSH2
expression is typically lost in colorectal or endometrial tumors
[13,14,16], high levels of MSH2 expression have also been
described in more malignant and proliferative melanoma and
salivary gland grade tumors [31,32].
Loss of protein expression could be due to aberrant DNA
methylation of cytosine residues in CpG promoter islands that
leads to transcriptional silencing of the associated genes [33].
We have found a specific association between MLH1
methylation of the proximal promoter region and the absence of
MLH1 expression in astrocytomas. Thus, we further confirm
that MLH1 proximal promoter methylation is important in
inhibiting MLH1 transcription as it has been previously reported
in colorectal cancer (CRC) [21]. Moreover, our results suggest
that MSH2 and MSH6 expression are not regulated by their
promoter methylation status in astrocytomas.
Analysis of the genotypic distribution of MLH1 -93G>A
polymorphism, located in a promoter region required for
maximal transcriptional activity [34], showed that the -93AA
genotype was associated with MLH1 promoter methylation and
deficient MLH1 expression never reported before in
astrocytomas. The -93AA genotype was also associated with a
higher risk of developing glioblastomas. This variant has been
Table 6. Differences in prognostic characteristics between
the study cohort and the validation cohort of high-grade
astrocytoma patients.
Patients, No. (%) Study cohort (n=72)
Validation cohort
(n=71) P-value
MSH6 expression   0.198
Positive 50 (69) 56 (79)  
Negative 22 (31) 15 (21)  
Age   0.359
<60 31 (43) 36 (51)  
≥60 41 (57) 35 (49)  
Treatment   < 0.001
No treatment 5 (7) 2 (3)  
Radiotherapy 47 (65) 12 (17)  
Radiotherapy and
Chemotherapy 20 (28) 57 (80)  
Median survival,
months [quartiles] 12.7 [10.1-15.3] 15.1 [10.8-19.4] 0.012
doi: 10.1371/journal.pone.0076401.t006
Mismatch Repair System and Astrocytomas
PLOS ONE | www.plosone.org 6 September 2013 | Volume 8 | Issue 9 | e76401
Figure 2.  Kaplan-Meier estimates of overall survival in
high-grade astrocytomas in the entire patient set
according to treatment received.  Treatment with both
radiotherapy and chemotherapy confers a significant increase
in overall survival time (A). Survival analysis in each treatment
group separately showed that loss of MSH6 expression
correlated with a better overall survival in patients receiving
radiation therapy alone (B), whereas MSH6 expression did not
modify prognosis of patients receiving both radiotherapy and
chemotherapy (C).
doi: 10.1371/journal.pone.0076401.g002
previously associated with loss of functional MMR system in
colorectal and endometrial cancers [17,18,35] and with an
increased risk of developing different tumors [17,36,37].
Nevertheless, further studies in larger series of patients are
necessary to confirm our observation.
MSI analysis revealed a low incidence of MSI-H tumors in
our series (5%) similar to that previously reported [38-41]. All
MSI-H cases were classified as glioblastomas, suggesting a
possible relation with higher proliferation cell levels. MSI is a
molecular feature resulting mainly from inactivating alterations
of the MMR system; however, loss of MMR protein expression
was not related to MSI status in our study. MMR deficiencies
are well associated with MSI status in several tumors, such as
ovarian, endometrial or colorectal cancers [11,14,42], but in
other tumors such as medulloblastoma or Ewing sarcoma this
association has not been reported [43,44]. These findings
suggest that MMR protein deficiencies are related to MSI
depending on the tumor type [44]. In addition, we observed that
BAT25 and BAT40 were the most frequent unstable markers in
astrocytomas instead of BAT26 that is the most unstable
marker in CRC. This difference might indicate that MSI in
astrocytomas is promoted by different mechanisms than in
CRC.
Search for mutations in MMR genes showed only two
pathogenic mutations. A germline pathogenic mutation in
MSH2 gene [27] was found in a MSI-H glioblastoma belonged
to a Lynch syndrome family. The other pathogenic mutation
was a novel somatic MSH2 mutation in a MSI-L glioblastoma
that also carried two additional variants of unknown
significance in MSH2 and MLH1 genes. One MLH1, one MSH2
and two MSH6 mutations of unknown significance that could be
causing the lack of expression of the associated proteins were
also detected. The absence of MMR gene mutations in most of
the sporadic MSI-H astrocytomas was in accordance with data
reported from sporadic CRC with high level of MSI that do not
harbor mutations in the repair genes [15,16].
Loss of MSH6 expression was more common than the
absence of MLH1 or MSH2 expression in our series,
suggesting an important role of this protein in the pathogenesis
of astrocytomas. It has been recently reported that MSH6
alterations arise in gliomas as a consequence of temozolomide
treatment [45,46]. Nevertheless, MSH6 alterations have also
been documented in pretreated astrocytoma tumors [47,48].
We must note that all cases included in our study were
analyzed before therapy, confirming that loss of MSH6
expression in astrocytomas is not always secondary to therapy-
induced mutagenesis.
Furthermore, survival analysis showed that loss of MSH6
expression was significantly associated with longer overall
survival in high-grade astrocytoma patients in our series.
Controversially, we did not find this association when we
analyzed MSH6 expression in an independent validation cohort
of high-grade astrocytoma patients. However, the treatment
approach was different between the two cohorts of patients due
to the different recruitment period of patients in each series.
For decades, postoperative radiotherapy has been the
standard treatment for newly diagnosed high-grade
astrocytomas [49]. However, since the 2005 publication of
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Stupp regimen [50], the established standard therapy for newly
diagnosed high-grade astrocytomas has been surgical
resection followed by radiotherapy with concomitant and
adjuvant chemotherapy with temozolomide with the
consequent significant increase in overall survival time
[3,50,51]. Therefore, survival analysis was performed in each
treatment group separately and revealed that loss of MSH6
expression was significantly associated with longer overall
survival in patients with high-grade astrocytomas treated with
radiotherapy alone, whereas no differences were found in
those patients that received radiotherapy plus chemotherapy.
The chemotherapy agent used in the majority of these patients
was the alkylating agent temozolomide.
Several studies have suggested that loss of MSH6 activity
confers resistance to temozolomide treatment in glioma and
may therefore contribute to progressive tumor growth and
tumor recurrence [45,46]. However, several analyses
concluded that MMR deficiency does not play a role in clinical
resistance to alkylator therapy in malignant gliomas [47]. This
finding was in accordance to our results that MSH6 expression
does not modify the prognosis of those patients treated with
radiotherapy and chemotherapy. On the other hand, the roles
of MMR deficiency in radiotherapy response are less clear. In
our series, loss of MSH6 expression confers a better prognosis
in high-grade astrocytomas treated only with radiotherapy
suggesting that MSH6 protein could modulate response to
radiation therapy in these tumors. It has been reported that loss
MSH6 expression in initial lesions was indicator of prolonged
survival in a group of patients treated mostly with postoperative
radiotherapy [48]. Ionizing radiation (IR) exposure induces a
wide variety of lethal DNA damage, especially double-strand
breaks (DSB). Although MSH6 plays a fundamental role in the
repair of mismatched DNA bases, recent studies demonstrated
that MSH6 contributes to DSB repair though the non-
homologous end-joining (NHEJ) pathway following IR exposure
by the interaction of MSH6 with Ku70 [52]. Thus, MSH6-
deficient cells have a major DSB repair defect and are more
sensitive to IR-induced cell death [52]. Therefore, our results
indicate that MSH6 expression might constitute a prognostic
marker for astrocytoma survival in patients treated only with
radiotherapy.
In summary, our results demonstrate that MMR system
alterations are a frequent event in malignant astrocytomas. We
suggest that analysis of MMR genes allows to define a subset
of astrocytomas with different outcome and could help to
search for new therapeutic strategies.
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